# Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Acute Treatment

> **NCT03924193** · PHASE3 · COMPLETED · sponsor: **Yale University** · enrollment: 141 (actual)

## Conditions studied

- Binge-Eating Disorder
- Obesity

## Interventions

- **DRUG:** Lisdexamfetamine Dimesylate
- **BEHAVIORAL:** Cognitive-Behavioral Therapy
- **OTHER:** Combination LDX and Cognitive-Behavioral Therapy

## Key facts

- **NCT ID:** NCT03924193
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-25
- **Primary completion:** 2023-09-13
- **Final completion:** 2023-09-13
- **Target enrollment:** 141 (ACTUAL)
- **Last updated:** 2024-10-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03924193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03924193, "Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Acute Treatment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03924193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*